Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

EQUIPMENT - Net 6,551,138 6,169,966

OTHER ASSETS

Deposit on patent license 2,910,446 --

Deposit on land use right 6,033,353 --

Intangible assets, net of

accumulated amortization 1,298,038 1,291,322

Deferred debt costs 265,377 --

Total Assets $49,016,208 $36,899,533

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:

Convertible debt, net of debt

discount $-- $2,561,645

Accounts payable and accrued

expenses 1,027,999 764,491

Value-added and service taxes

payable 2,030,543 572,200

Advances from customers -- 34,531

Unearned revenue 641,162 530,063

Due to related parties 1,272,153 323,178

Total Current Liabilities 4,971,857 4,786,108

LONG-TERM LIABILITIES:

Due to related parties 654,850 738,300

Notes payable - related parties 5,043,500 4,738,508

Series A convertible redeemable

preferred stock, $.001 par

value; 10,000,000 shares

authorized; 5,747,118 and - 0 -

shares issued and outstanding

at June 31, 2008 and

December 31, 2007, respectively 3,305,813 --

Total Liabilities 13,976,020 10,262,916

SHAREHOLDERS' EQUITY:

Common stock ($.001 par value;

200,000,000 shares authorized;

42,420,239 and 41,794,200

sha
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... September 30, 2014 Each year ... injuries require medical attention. In the military, burn ... complications to battlefield medical care. More than 800 ... Afghanistan. Burn wounds heal slowly, remain inflamed and ... excessive, physically debilitating and functionally damaging. While developments ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
(Date:9/29/2014)... 2014 Research and Markets  has announced ... Product & Services, End-User , Application - Global Forecast ... The global oligonucleotide synthesis market is expected to ... 2014, growing at a CAGR of 9.8% from 2014 ... on the basis of products and services, applications, end ...
Breaking Biology Technology:ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Faster Healing with Fewer Scars 2Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3
... ... the International Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix is issuing the following ... 2020 or beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:, , ,“We are ...
... , SAN FRANCISCO , Feb. 1 ... acted as a placement agent in GenVec, Inc.,s (Nasdaq: GNVC ... of common stock, and warrants to purchase 4.2 million shares of ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with the ...
... , GEORGETOWN, Texas , Feb. 1 ... on the treatment of degenerative disc disease and low back pain, ... Small Business Innovation Research (SBIR) Grant from the National Institutes of ... , Dr. Thomas Hedman , Ph.D., Founder and CSO of ...
Cached Biology Technology:Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Intralink-Spine Inc. Awarded $750,000 Small Business Innovation Research Phase II Grant 2
(Date:9/30/2014)... LIVERMORE, Calif. The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama,s BRAIN (Brain ... new research effort to revolutionize our understanding of ...
(Date:9/30/2014)... environmental scientists and engineers, led by Clemson University ... $5.25 million grant from the U.S. Department of ... make a direct positive impact on South Carolina ... of radioactive contaminants. , "Understanding the scientific and ... environmental aspects of nuclear technologies is imperative if ...
(Date:9/30/2014)... The New England Journal of Medicine reports ... the drug crizotinib against the subset of lung cancer ... multi-center study of 50 patients with advanced non-small cell ... response rate was 72 percent, with 3 complete responses ... time it takes for the disease to resume its ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... into a lock may seem like a simple task, but ... involves testing thousands of keys to unlock the functions of ... targets for drug designs. Texas A&M researcher Frank Raushel ... technique called molecular docking to predict which molecule, called a ...
... cancer before it has a chance to take root and ... in cancer prevention. Leading experts from around the globe are ... promising new field, with the hope this work will significantly ... prevention relies heavily on: , identifying promising targets ...
... blood is undertaken by hemoglobin, the largest component of ... organs, mainly in the lungs, and releases it in ... cell survival. Hemoglobin is one of the most refined ... structure can produce anaemia and other severe pathologies. ...
Cached Biology News:Unlocking the function of enzymes 2Hemoglobin uncovered 2
... allows real-time observations of cell cultures under ... 64 different strain parameters in addition to ... silicon strain chamber used by the ST-195 ... microscopy. ST-195 can be used with Nikon, ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... EasyCount ViaSure Kit is used in conjunction with ... nucleated cells automatically. The ViaSure Staining Reagent ... - Acridine Orange and Ethidium Bromide to identify ... test, while the EasyCount Slide 6 Multi-well ...
... provides a powerful yet simple technology for ... The kit provides the heterobifunctional linkers SFB ... conjugation efficiencies. It enables conjugation of various ... tags with a variety of proteins. ...
Biology Products: